|
FAF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
6.2703999999969E-05 |
| Normal-vs-Stage3 |
8.99299967827005E-10 |
| Normal-vs-Stage4 |
1.91010540717684E-11 |
| Stage1-vs-Stage2 |
4.394200E-01 |
| Stage1-vs-Stage3 |
2.842600E-01 |
| Stage1-vs-Stage4 |
2.055000E-01 |
| Stage2-vs-Stage3 |
9.927200E-01 |
| Stage2-vs-Stage4 |
1.297170E-01 |
| Stage3-vs-Stage4 |
5.668000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62536650805123E-12 |
| Normal-vs-AfricanAmerican |
2.61270000001534E-06 |
| Normal-vs-Asian |
2.93409962992541E-10 |
| Caucasian-vs-AfricanAmerican |
4.202400E-02 |
| Caucasian-vs-Asian |
1.434440E-01 |
| AfricanAmerican-vs-Asian |
3.939000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.64135371960583E-12 |
| Normal-vs-Female |
3.33066907387547E-16 |
| Male-vs-Female |
4.888600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
1.7000845176085E-12 |
| Normal-vs-Age(61-80Yrs) |
1.20900000011304E-08 |
| Normal-vs-Age(81-100Yrs) |
3.411600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.191200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.251600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.674100E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.090200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.097430E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.792410E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.386300E-02 |
| Classical-VS-Follicular |
1.197850E-03 |
| Classical-VS-Other |
6.762800E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
4.017800E-01 |
| Tall-VS-Other |
7.474800E-01 |
| Tall-VS-Normal |
2.86609999955445E-07 |
| Follicular-VS-Other |
5.431400E-01 |
| Follicular-VS-Normal |
2.33259999999902E-05 |
| Other-VS-Normal |
6.702100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.45280470881448E-11 |
| Normal-vs-N1 |
3.70210000433246E-08 |
| N0-vs-N1 |
5.241800E-01 |
|
|
